FDA grants Orphan Drug Designation for prosetin for treatment of amyotrophic lateral sclerosis
Prosetin is an investigational oral, metabolically stable, and blood-brain barrier-penetrant MAP4 kinase inhibitor which works by protecting motor neurons from endoplasmic reticulum stress-mediated degeneration
Source:
Biospace Inc.